
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -1.54394299287 | 8.42 | 8.53 | 7.87 | 807466 | 8.20148408 | CS |
4 | 0.1 | 1.221001221 | 8.19 | 9.16 | 7.52 | 1904372 | 8.4439153 | CS |
12 | -2.85 | -25.5834829443 | 11.14 | 11.62 | 6.98 | 1779920 | 8.80489311 | CS |
26 | -11.74 | -58.6120818772 | 20.03 | 21.569 | 6.98 | 1409003 | 11.31530269 | CS |
52 | -12.21 | -59.5609756098 | 20.5 | 24.17 | 6.98 | 1099376 | 14.69041065 | CS |
156 | -5.57 | -40.1875901876 | 13.86 | 24.17 | 6.98 | 948298 | 14.09722093 | CS |
260 | -3.88 | -31.8816762531 | 12.17 | 42.82 | 6.34 | 844743 | 16.81734793 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.